Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion

By Zacks Investment ResearchStock MarketsApr 03, 2018 10:56PM ET
www.investing.com/analysis/biotech-stock-roundup-edge-falls-alks-down-fda-oks-amgn-drug-label-expansion-200303083
Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion
By Zacks Investment Research   |  Apr 03, 2018 10:56PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

It was a week that saw Edge Therapeutics crashing on news of discontinuation of its phase III study, Amgen’s Blincyto getting FDA’s nod for label expansion, EMA accepting Regeneron & Sanofi’s application for label expansion of Dupixent.

Recap of the Past Week’s Most Important Stories

Edge Therapeutics Plummets on Failure of Late-Stage Study: Edge Therapeutics, Inc. (NASDAQ:EDGE) lost almost 92% after the company announced disappointing results from a phase III study, NEWTON 2 on lead pipeline candidate, EG-1962 for the treatment of adults with aneurysmal subarachnoid hemorrhage (aSAH). NEWTON 2 study compared the efficacy and safety of EG-1962 (nimodipine microparticles) to standard of care oral nimodipine in adult patients with aSAH. A pre-specified interim analysis performed on data from the day 90 visit of the first 210 subjects randomized and treated in the study demonstrated a low probability of achieving a statistically-significant difference compared to the standard of care in the study’s primary endpoint if the study is fully enrolled. The independent Data Monitoring Committee (“DMC”) recommended that the study be stopped based on its conclusion that it has a low probability of meeting its primary endpoint. Consequently, Edge Therapeutics has decided to discontinue the NEWTON 2 study. Moreover, the company will reduce the size of its workforce, in order to preserve cash resources, which were $88.1 million as of Dec 31, 2017 due to the failure of the late-stage study. It was the company’s lead candidate and the failure of the study puts a question on its prospects. (Read more: Edge Therapeutics Loses Edge on Failure of Late-Stage Study)

Alkermes Plunges on FDA’s Refusal to File Letter for ALKS 5461: Shares of Alkermes plc (NASDAQ:ALKS) plunged significantly after the company received a Refusal to File letter from the FDA regarding its New Drug Application (“NDA”) for anti-depressant ALKS 5461. ALKS 5461 was being evaluated for the adjunctive treatment of major depressive disorder (“MDD”) in patients with an inadequate response to standard antidepressant therapies. The FDA notified the company that the agency was not able to complete a substantive review due to lack of sufficient evidence of overall efficacy of the candidate for the proposed indication. The FDA has also asked the company to conduct additional well-controlled clinical trials to be able to resubmit the NDA. Moreover, the FDA has also requested the company to conduct a bioavailability study to generate additional bridging data between ALKS 5461 and the reference listed drug, buprenorphine. However, Alkermes plans to appeal the FDA's decision, requesting a Type A meeting with the FDA, to determine the next course of action and additional information required for the resubmission of the NDA (Read more: Alkermes Sinks as FDA Refuses Depression Drug Review)

Amgen Gets Approval for Label Expansion of Drugs: The FDA approved a label expansion of Amgen Inc. ’s (NASDAQ:AMGN) leukemia drug Blincyto for the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease (“MRD”) greater than or equal to 0.1% under accelerated approval basis. The acclereated approval was based on MRD response rate and hematological relapse-free survival. In addition, the European Commission approved a label expansion of Xvega to include the prevention of skeletal-related events in adults with advanced malignancies involving bone. Xgeva is already approved for the prevention of skeletal-related events in patients with bone metastases from solid tumors. With the latest approval, the European label of Xgeva will be expanded to include patients with multiple myeloma. (Read more: Amgen's Xgeva Gets EU Approval for Expanded Label,Amgen's Blincyto Gets FDA Nod for Minimum Residual Disease)

EMA Accepts Dupixent label expansion and cemiplimab for Review: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and partner Sanofi (NYSE:SNY) announced that the European Medicines Agency (“EMA”) has accepted the companies’ application for an additional indication for Dupixent. Both companies are seeking the agency’s approval for Dupixent use as an add-on maintenance treatment in certain adults and adolescents (12 years of age or older) with inadequately controlled moderate-to-severe asthma. Dupixent is already approved in the United States and the European Union for the treatment of adults with moderate-to-severe atopic dermatitis. The EMA has also accepted the Marketing Authorization Application for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (“CSCC”) or patients with locally advanced CSCC who are not eligible for surgery. (Read more: EMA Accepts Regeneron/Sanofi's application for Dupixent, Sanofi's Skin Cancer Candidate Filing Accepted in EU)

Regeneron currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Performance

Medical - Biomedical and Genetics Industry 5YR % Return

Medical - Biomedical and Genetics Industry 5YR % Return

The NASDAQ Biotechnology Index lost 2.89% over the last four trading sessions. Among major biotech stocks, Alexion lost 2.83%%. Over the last six months, Celgene (NASDAQ:CELG) lost 40.56% while Vertex gained 3.84% (see the last biotech stock roundup here: Biotech Stock Roundup: PTGX Down, VRNA Up, AMGN's Repatha Gets Positive Opinion).

What's Next in the Biotech World?

Stay tuned for more regulatory and pipeline updates.

Wall Street’s Next Amazon (NASDAQ:AMZN)

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>



Sanofi (SNY): Free Stock Analysis Report

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

Alkermes plc (ALKS): Free Stock Analysis Report

Amgen Inc. (AMGN): Free Stock Analysis Report

Original post

Zacks Investment Research
Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion
 

Related Articles

Lance Roberts
Is The Omicron Selloff Over Yet? By Lance Roberts - Dec 05, 2021 2

What’s Really Driving The Omicron Market SelloffWhile the media is running around trying to pin headlines on the market moves from the Fed to the Omicron variant, the reality...

Biotech Stock Roundup: EDGE Falls, ALKS Down, FDA OK's AMGN Drug Label Expansion

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email